Zacks Investment Research upgraded shares of SenesTech (NASDAQ:SNES) from a sell rating to a hold rating in a research note published on Thursday.
According to Zacks, “SenesTech, Inc. developed technology for managing animal pest populations through fertility control as opposed to a lethal approach. The Company’s fertility control product candidate, ContraPest(R), will be marketed for use initially in controlling rat infestations. SenesTech, Inc. is based in Flagstaff, Arizona. “
A number of other research analysts have also weighed in on the stock. ValuEngine upgraded shares of SenesTech from a strong sell rating to a sell rating in a research note on Friday, February 2nd. Roth Capital reduced their price target on shares of SenesTech from $3.75 to $14.00 and set a buy rating for the company in a research report on Thursday, December 28th. Finally, Craig Hallum set a $3.00 price target on shares of SenesTech and gave the company a buy rating in a research report on Wednesday, November 22nd.
SenesTech (SNES) opened at $0.68 on Thursday. SenesTech has a one year low of $0.56 and a one year high of $9.60. The company has a quick ratio of 2.67, a current ratio of 2.94 and a debt-to-equity ratio of 0.17.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Gilder Gagnon Howe & Co. LLC grew its position in shares of SenesTech by 3.0% during the 3rd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,078,499 shares of the company’s stock valued at $1,995,000 after purchasing an additional 31,330 shares in the last quarter. Skylands Capital LLC grew its position in shares of SenesTech by 140.1% during the 4th quarter. Skylands Capital LLC now owns 210,017 shares of the company’s stock valued at $151,000 after purchasing an additional 122,534 shares in the last quarter. TCI Wealth Advisors Inc. purchased a new position in shares of SenesTech during the 3rd quarter valued at $748,000. Finally, Sabby Management LLC purchased a new position in shares of SenesTech during the 4th quarter valued at $315,000. Hedge funds and other institutional investors own 16.14% of the company’s stock.
SenesTech, Inc is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.